Skip to content

Radiofrequency ablation of abdominal wall endometriosis

Safety and efficacy of Radiofrequency ablation of abdominal wall endometriosis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220219054066N1
Enrollment
10
Registered
2022-09-29
Start date
2022-10-27
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal wall endometriosis. Endometriosis, unspecified

Interventions

After determining the volume of the lesions with ultrasound, the patients with receive general anesthesia and local anesthesia will be achieved with a subcutaneous injection of 1% Lidocaine. Then Radi

Sponsors

Iranian academic center for education culture and research
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Abdominal Wall Endometriosis diagnosis no history of abdominal wall surgery over the past three months patients without severe comorbidities, such as hypertension or diabetes patients could tolerate 1-2 hours under general anesthesia

Exclusion criteria

Exclusion criteria: Patients with more than 1 abdominal wall endometriosis lesion Abdominal wall endometriosis lesion volume of over 50 cc Past surgical history of resection of abdominal wall endometriosis Past medical history of heart failure Allergy to cephalexin and lidocain

Design outcomes

Primary

MeasureTime frame
Pain score on Visual Analogue Scale. Timepoint: Pain score at the beginning of the study and 30, 90 and 180 days after treatment. Method of measurement: Visual Analogue Scale.;The volume of the lesions in abdominal Ultrasound. Timepoint: The volume of the lesions at the beginning of the study and 30, 90 and 180 days after treatment. Method of measurement: Abdominal ultrasound.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Ali Forouzannia

Shahid Beheshti University of Medical Sciences

s.ali.forouzannia@sbmu.ac.ir+98 21 2613 2119

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026